


CLAIMS

1. A compound and pharmaceutically acceptable salts thereof according to structural formula (I):




wherein:

R¹ is OH, N-alkyl, one or more amino acids;

each of R² and R³ is independently OH, N₃, hydrogen, halo, alkyl, alkoxy, amines or absent and linked via an alkene; and

R⁴ is a heterocycle.

2. The compound of claim 1 and pharmaceutically acceptable salts thereof according to structural formula (II):




wherein:

R¹ is OH, N-alkyl, one or more amino acids;

each of R² and R³ is independently OH, N₃, hydrogen, halo, alkyl, alkoxy, or amine; and

R⁵ is OH, N₃, hydrogen, halo, alkyl, alkoxy, or amine.

3. The compound of claim 1 and pharmaceutically acceptable salts thereof according to structural formula (III):



wherein:

R¹ is OH, N-alkyl, one or more amino acid;

each of R² and R³ is independently OH, N₃, hydrogen, halo, alkyl, alkoxy, or amine; and

R⁵ is OH, N₃, hydrogen, halo, alkyl, alkoxy, or amine.

4. A pharmaceutical composition comprising a compound according to any one of claims 1-3, and a pharmaceutically acceptable carrier, diluent, or excipient.

5. A method of treating or preventing a disease or condition associated with DNA or RNA processing enzymes, comprising administering to a subject in need thereof a pharmaceutical composition of claim 4 in an amount effective to treat or prevent said disease or condition associated with DNA or RNA processing enzymes.

6. The method of claim 5 wherein the disease or condition is a viral disease.

7. The method of claim 6 wherein the viral disease is caused by hepatitis C virus (HCV) or human immunodeficiency virus (HIV).

8. The method of claim 5 wherein said composition further comprises a second therapeutic agent.

9. The method of claim 5 wherein said composition further comprises a second therapeutic agent selected from the group consisting of an inhibitor of nucleoside reverse transcriptase, a non-nucleoside reverse transcriptase inhibitor, a helicase inhibitor, an RNase H inhibitor, a kinase inhibitor, and a protease inhibitor.

10. A method of modulating the activity of a DNA or RNA processing enzymes, the method comprising contacting a DNA or RNA processing enzyme with a modulatory amount of a compound or composition as described in any one of claims 1-4.

11. The method of claim 10 wherein the DNA or RNA processing enzyme being modulated is RNA-dependent RNA polymerase.

12. The method of claim 11 wherein the RNA-dependent RNA polymerase is non-structural protein 5B from HCV.